Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Tvardi Therapeutics (TVRD) EPS (Basic) (2016 - 2025)

Tvardi Therapeutics' EPS (Basic) history spans 13 years, with the latest figure at -$0.84 for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 83.0% to -$0.84 in Q4 2025 year-over-year; TTM through Dec 2025 was -$4.14, a 86.21% increase, with the full-year FY2025 number at -$2.46, up 78.46% from a year prior.
  • EPS (Basic) hit -$0.84 in Q4 2025 for Tvardi Therapeutics, down from -$0.59 in the prior quarter.
  • Over the last five years, EPS (Basic) for TVRD hit a ceiling of $0.51 in Q2 2025 and a floor of -$24.67 in Q4 2023.
  • Historically, EPS (Basic) has averaged -$4.06 across 5 years, with a median of -$0.6 in 2021.
  • Biggest five-year swings in EPS (Basic): crashed 4030.61% in 2024 and later soared 118.82% in 2025.
  • Tracing TVRD's EPS (Basic) over 5 years: stood at -$0.64 in 2021, then tumbled by 2726.56% to -$18.09 in 2022, then tumbled by 36.37% to -$24.67 in 2023, then skyrocketed by 79.98% to -$4.94 in 2024, then soared by 83.0% to -$0.84 in 2025.
  • Business Quant data shows EPS (Basic) for TVRD at -$0.84 in Q4 2025, -$0.59 in Q3 2025, and $0.51 in Q2 2025.